Preclinical differentiation of low molecular weight heparins

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 3, 1999, Pages 63-72

  Nader, Helena B ^a,b,c,d   Walenga, Jeanine M ^a,b   Berkowitz, Scott D ^a   Ofosu, Frederick ^a,b,e   Hoppensteadt, Debra A ^b,c,d,e   Cella, Giuseppe ^a,b,c,d,e  

^a Departmenta de Bioqiiimica   (Brazil)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; BLOOD CLOTTING FACTOR 7A; CERTOPARIN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; REVIPARIN; THROMBOPLASTIN; TINZAPARIN; UNCLASSIFIED DRUG;

BINDING AFFINITY; BIOEQUIVALENCE; CONFERENCE PAPER; DEPOLYMERIZATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

ANIMALS; BIOLOGICAL AVAILABILITY; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PROTHROMBIN; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 0032702380     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hirsh J, Levine N. Low molecular weight heparin: Laboratory properties and clinical evaluation. Eur J Surg 1994;157(Suppl):9-22
2. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga J. Low molecular weight heparins: Pharmacologie profile and product differentiation. Am J Cardiol 1998;82:3L-10L
3. Ofosu FA, BarrowcliffeTW. Mechanisms of action of low molecular weight heparins and heparinoids. In Hirsh J, ed. Antithrombotic Therapy. Bailiere's Clinical Haematology, volume 3. London: BailiereTindall Ltd, 1990:505-529
4. Bianchini P, Osima B, Parma B, et al. Structural studies, and in vivo and in vitro pharmacological activities of heparin fractions and fragments prepared by chemical and enzymatic depolymerization. Thromb Res 1985;40:49-58
5. Holmer E, Soderberg K, Bergqvist D, Lindahl U. Heparin and its low molecular weight derivatives: Anticoagulant and antithrombotic properties. Haemostasis 1986;16(Suppl 2):l-7
6. Branellec JF, Espego J, Picart P. Purified heparin fractions, method for obtaining them and pharmaceutical compositions containing them. US patent #5599801, 1997.
7. Desai UR, Linhardt RJ. Molecular weight of low molecular weight heparin by I3C nuclear magnetic resonance spectroscopy. Carbohydr Res 1994:255:193-212.
8. Rice KG, Kim YS, Grant AC, Merchant ZM, Linhardt RJ. High-performance liquid Chromatographie separation of heparin derived oligosaccharides. Anal Biochem 1985;150: 325-331
9. Edens RE, Al-Hakim A, Weiler JM, et al. Gradient polyacrylamide gel electrophoresis for determination of the molecular weights of herparin preparations and low molecular weight heparin derivatives. J Pharm Sei 1992;81:823-827
10. Jeske W, Iqbal O, Gonnela S, et. al. Pharmacologie profile of a low molecular weight heparin depolymerized by -yirradiation. Semin Thromb Hemostas 1995:21:201-211
11. Pervin A, Gallo C, Jandik KA, Han X-J, Linhardt RJ. Preparation and structural characterization of large herparin-derived oligosaccharides. Glycobiology, 1995;5:83-95
12. Casu B. Protein binding of sulfated glycosaminoglycans: searching for specificity. In: Nonanticoagulant action of glycosaminoglycans, Harenberg J., Casu B., eds. New York: Plenum Press: 1996:89-99
13. HilemanRE, Fromm JR, Weiler JM, Linhardt RJ. Glycosaminoglycan-protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins. BioEssays 1998:20:156-167
14. Poletti LF, Bird KE, Marques D, et al. Structural aspects of heparin responsible for interactions with von Willebrand factor. Arterioscler Thromb Vase Biol 1997;17:925-931
15. Bianchini P, Osima B, Parma B, Nader HB, Dietrich CP. Lack of correlation between in vitro and in vivo antithrombotic activity of heparin fractions and related compounds. Heparin sulfate as an antithrombotic agent in vivo. Thromb Res 1985; 40:597-607
16. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low molecular weight heparin preparations the same? Semin Thromb Hemost 1996;22(Suppl 1):77-91
17. Nader HB, Porcionatto MA, Tersariol ILS, et al. Purification and substrate specificity of heparitinase I and heparitinase II from Flavobacteriiim heparimnn. Analysis of the heparin and heparin sulfate degradation products by "C NMR spectroscopy. J Biol Chem 1990;265:6807-6813
18. Bisio A, Guerrini M, Yates EA, Torri G, Casu B. NMR indentification of structural environments for 2,3 or 2,3,6 tri-sul fated glucosamine residues in heparin with high and no affinity for antithrombin. Glycoconj J 1997:14 (Suppl I):S89
19. Mulloy B, Johnson EA. Assignment of the H-NMR spectra of heparin and heparansulfate. Carbohydr Res 1987:170: 151-165
20. Casu B, Guerrini M, Naggi A, Torri G. NMR spectroscopic differentiation between beef and pig mucosal heparins. Thromb Haemost 1995:74:1205
21. Baram D, Rashkovsky M, Hershkoviz R, et al. Inhibitory effects of low molecular weight heparin on mediator release by mast cells: Preferential inhibition of cytokine production and mast cell dependant cutaneous inflammation. Clin Exp Immunol 1997; 110:485-491
22. Engstad CS, Gutteburg TJ, Osterud B Modulation of blood cell activation by four commonly used anticoagulents. Throm Haemstas 1997;77:690-696
23. McBride \VT, Armstrong MA, McMurray TJ. An investigation of the effects of heparin, low molecular weight heparin, protamine and fentanyl on the balance of pro- and anti-inflammatory cytokines in in-vitro monosyte cultures. Anaesthesia 1996; 51-.634-640
24. Jayson GC, Gallagher JT Heparin oligosaccharides: Inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer 1997;75:9-16
25. Lustig F, Hoebeke J, Ostergren-Lunden G, et al. Alternative splicing determines the binding of platlet-derived growth factor (PDGF-AA) to glycosaminoglycans. Biochemistry 1996; 35: 12077-12085
26. Stehle G, Wunder A, Sinn H, Schrenk HH, et al. Pharmacokinetic properties of LM\V-heparin-tyramine fractions with high or lovy affinity to antithrombin III in the rat. Semin Thromb Hemost 1997;23(l):31-7
27. Haba M, Urano K, Yusasa H, Watanabe J. Molecular weight dependancy in the uptake of fractionated [3H]heparin in isolated rat Kupffer cells. Biol Pharm Bull 1996 Jun;19(6): 864-8
28. Loganathan D, Wang HM, Malus LM, Linhardt RJ. Structural variation in the antithrombin III binding site region ond its occurence in heparin from different sources. Biochemistry 1990;29:4362-4368
29. Brieger D, Dawer J. Production method effects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997;77(2):317-322
30. Agnelli G. Pharmacological activities of heparin chains: Should our past knowledge be revised? Haemostasis 1996;26(Suppl 2):2-9
31. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin, and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995;73:630-640
32. Peyrou V, Lormeau JC, Hérault JP, Boneu B, Herbert JM. Longterm persistence of low molecular weight material with antifactor Xa activity contributes to anticoagulant and antithrombotic effects after subcutaneous injection of CY 216 in the rabbit. Blood Coag Fibrinolysis 1997;8:175-184
33. Mismetti P, Laporte-Simitsidis S, Navarro C, et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemostas 1998;79: 1162-1165
34. Hirsh J, Levine MM. Low molecular weight heparin. Blood 1992;79:1-17
35. Planes A, Vochelle N, Fagola M, Bellaud M. Comparison of two low molecular weight heparins for the prevention of postoperative venous tromboembolism after elective hip surgery. Revparin Study Group. Blood Coag Fibrinolysis 1998;9(6):499-505
36. Planes A, Samama MM, Lensing AW, et al. Prevention of deep vein thrombosis after hip replacement-comparison between two low molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;81(l):22-25
37. Abbate R, Gori AM, Farsi A, Attanasio M, Pepe G. Monitoring of low molecular weight heparins in cardiovascular disease. Am J Cardiol 1998;82:33L-36L
38. Farced J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins: A developmental perspective. Exp Opin Invest Drugs 1997;6:706-733
39. Hoppensteadt DA, Jeske W, Fareed F, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low molecular weight heparin. Blood Coag Fibrinolysis 1995;6:S57
40. Piazolo L, Harenberg J, Maisch R, Huttner FG, Heene DL. Comparison of the pharmacodynamic and pharmacokinetic profiles of two low molecular mass heparins in rats. Semin Thromb Hemost 1997;23:109-116